Discovery and canine preclinical assessment of a nontoxic procaspase-3-activating compound - Wikidata - wikimedia - TriplyDB

Discovery and canine preclinical assessment of a nontoxic procaspase-3-activating compound

Discovery and canine preclinical assessment of a nontoxic procaspase-3-activating compound

http://www.wikidata.org/entity/Q28292596

about

Targeting the apoptosis pathway in hematologic malignancies Dual small-molecule targeting of procaspase-3 dramatically enhances zymogen activation and anticancer activity Small-Molecule Procaspase-3 Activation Sensitizes Cancer to Treatment with Diverse Chemotherapeutics ERO1α-dependent endoplasmic reticulum-mitochondrial calcium flux contributes to ER stress and mitochondrial permeabilization by procaspase-activating compound-1 (PAC-1).Parallel synthesis and biological evaluation of 837 analogues of procaspase-activating compound 1 (PAC-1)Caspase functions in cell death and disease.Expression of executioner procaspases and their activation by a procaspase-activating compound in chronic lymphocytic leukemia cells FRET-based and other fluorescent proteinase probes.Removal of Metabolic Liabilities Enables Development of Derivatives of Procaspase-Activating Compound 1 (PAC-1) with Improved Pharmacokinetics Derivatives of Procaspase-Activating Compound 1 (PAC-1) and their Anticancer Activities.Differential effects of procaspase-3 activating compounds in the induction of cancer cell death.Targeting procaspase-3 with WF-208, a novel PAC-1 derivative, causes selective cancer cell apoptosis Molecular evidence of Zn chelation of the procaspase activating compound B-PAC-1 in B cell lymphoma.Canine lymphoma as a comparative model for human non-Hodgkin lymphoma: recent progress and applications Defining the Value of a Comparative Approach to Cancer Drug Development.Small molecules as pro-apoptotic anticancer agents.SM-1, a novel PAC-1 derivative, activates procaspase-3 and causes cancer cell apoptosis.The Combination of Vemurafenib and Procaspase-3 Activation Is Synergistic in Mutant BRAF Melanomas.Breast cancer gene therapy using an adenovirus encoding human IL-2 under control of mammaglobin promoter/enhancer sequences.A novel small-molecule activator of procaspase-3 induces apoptosis in cancer cells and reduces tumor growth in human breast, liver and gallbladder cancer xenografts.Grand challenge commentary: Informative diagnostics for personalized medicine.Analysis of apoptosis methods recently used in Cancer Research and Cell Death & Disease publications.Synergistic and targeted therapy with a procaspase-3 activator and temozolomide extends survival in glioma rodent models and is feasible for the treatment of canine malignant glioma patients.

P2860

Q27024422-CA3A041A-82F5-422B-9AED-92C2F03019B8 Q28304985-FB207F8C-EE45-46A9-8E3A-5CA1EC0D622B Q29027136-B32488D9-0390-4C7D-B1DC-6F962362A215 Q30561116-A99A9FA6-BC24-4DA7-B8D2-0B729BA5F6D6 Q34050598-4A8CF8C9-100E-46F7-91FA-D558F93BA86E Q34336335-3B0FA82A-380E-47A6-91AE-8056C373B117 Q34455521-0F473E98-1467-42CE-AC5E-4BD267E78D7D Q35086168-73E10642-027D-4E4E-B64B-9F4AA58BD466 Q35598226-6A49E320-6A88-4DB0-A384-FE22A253FB63 Q35859325-F7FEF1E5-0E3D-40C6-BFF9-66F7DC039152 Q35946431-0C5D1EC2-B281-4AB2-964B-B7EE0F2018C4 Q35995093-C67E98BB-8971-415C-B12C-1B00B51C29C8 Q36772172-524A1C15-C716-4C2A-8D21-5664EF51D63E Q37196999-1FC28FA9-1DD1-4A4F-B9C4-61A40E7C38B5 Q37417714-A44C0E8E-7612-4248-B1DF-B6318DE26D92 Q38162939-CE4C7E73-133A-4C4D-9D85-B12EDB23BEA5 Q38753997-3E86323D-EE78-4908-BAF8-851FFCBABA65 Q38764663-678BEF82-AC17-4BB0-9426-A6D129E7E925 Q38772887-F6D35437-F793-404F-8F9F-E3512E0179CC Q38972543-65E05479-CA91-4D3C-BBDB-80BCCBBE4124 Q42035610-A8CC6C43-70F9-4D82-8307-FAD28CF9DA31 Q42632659-1A28AFB8-4F6E-4C40-A7DB-F2CBD53BD9EA Q46549141-4E66ECB8-5E73-40D8-B741-CC991D078C64

P2860

Discovery and canine preclinical assessment of a nontoxic procaspase-3-activating compound

http://www.wikidata.org/entity/Q28292596

description

2010 nî lūn-bûn

@nan

2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Discovery and canine preclinic ...... ocaspase-3-activating compound

@ast

Discovery and canine preclinic ...... ocaspase-3-activating compound

@en

Discovery and canine preclinic ...... ocaspase-3-activating compound

@nl

type

label

Discovery and canine preclinic ...... ocaspase-3-activating compound

@ast

Discovery and canine preclinic ...... ocaspase-3-activating compound

@en

Discovery and canine preclinic ...... ocaspase-3-activating compound

@nl

prefLabel

Discovery and canine preclinic ...... ocaspase-3-activating compound

@ast

Discovery and canine preclinic ...... ocaspase-3-activating compound

@en

Discovery and canine preclinic ...... ocaspase-3-activating compound

@nl

P1433

Q28292596-733F9E9C-D143-47D0-8BBF-C6D3849A4926

P1476

Q28292596-A638FF85-FC2C-4CF6-A1A6-2C06E16C9787

P2093

Q28292596-0C8464B0-C429-45CD-8D55-596D77FD580A

Q28292596-1E52E0E1-E2E2-4E94-8907-A82607E6C08B

Q28292596-2423AF7B-29EF-4E6D-98A8-0AC7A5514DD6

Q28292596-46000BB4-68CE-4BCB-BD9C-C5D4B2FA402E

Q28292596-657B59C7-DBAF-4C67-9615-65F13FB11C50

Q28292596-8DA57FB3-149E-4D99-9EFE-7E59FA907917

Q28292596-A09ABC61-427F-488F-887C-AA123BB9EB4F

Q28292596-EC992640-3DFC-415A-843C-01E0056A4758

P2860

Q28292596-00DEBD06-70E7-4CC2-AE1B-3D59F647E998

Q28292596-025A28BF-2D0A-4F73-9EA3-C2AB3B2AC524

Q28292596-0A142277-6E4B-4BE2-BA2F-252E6E0A8C0F

Q28292596-11EFB3AF-2AF6-4693-8823-4662FF6CE9FE

Q28292596-1BA750FC-D9F2-482B-A200-3F7EC657CFDF

Q28292596-22EE2E80-1099-4B58-801A-3021A3CB6EFE

Q28292596-25B849C7-F84F-454C-BECC-6B6A636BB77C

Q28292596-35469F61-34CA-4D2D-AFD4-DEE07C83CCFE

Q28292596-356C809D-2743-46E6-BC9F-57ABAF00369D

Q28292596-39E7C017-C64F-4614-9CE9-157950306E86

P304

Q28292596-3978A2C0-BB18-4C1D-AFD1-152671B98A4D

P31

Q28292596-104A5D62-C703-4A9D-8D36-7A388637A413

P3181

Q28292596-9954141A-D892-48EC-A83D-808893A94098

P356

Q28292596-4D3A014A-9D7B-40E3-A207-421A7F41E1AB

P407

Q28292596-38B6B551-EA61-46BF-9FFF-7BBA3AE21D25

P433

Q28292596-671F3FE2-3CF4-40E1-BD82-EA98CBB6D453

P478

Q28292596-4266B194-BD75-4163-87F2-70E6CE28644F

P50

Q28292596-87C0CE63-3B88-4FF7-A4E6-739671FA2FC5

P577

Q28292596-F6C73DD8-F5A7-46B0-BE13-3F2010D76E4A

P5875

Q28292596-3BCB3A7E-8E38-430B-84A8-8F84E9B3AD9A

P698

Q28292596-8807B608-E33D-499A-83EB-06165E6F430B

P932

Q28292596-7C0445F7-E120-45AD-8F88-3361799DBAAD

P3181

P356

0008-5472.CAN-10-0766

P1433

Cancer Research

P1476

Discovery and canine preclinic ...... ocaspase-3-activating compound

@en

P2093

Chris J Novotny

http://www.w3.org/2001/XMLSchema#string

Danny C Hsu

http://www.w3.org/2001/XMLSchema#string

Dewey Kim

http://www.w3.org/2001/XMLSchema#string

Diana C West

http://www.w3.org/2001/XMLSchema#string

Joanna M Schmit

http://www.w3.org/2001/XMLSchema#string

Levent Dirikolu

http://www.w3.org/2001/XMLSchema#string

Paul J Hergenrother

http://www.w3.org/2001/XMLSchema#string

Timothy M Fan

http://www.w3.org/2001/XMLSchema#string

P2860

Chemotherapy combinations with monoclonal antibodies in non-Hodgkin's lymphoma

Structure of the zinc-bound amino-terminal domain of the NMDA receptor NR2B subunit

PAC-1 activates procaspase-3 in vitro through relief of zinc-mediated inhibition

Procaspase-3 activation as an anti-cancer strategy: structure-activity relationship of procaspase-activating compound 1 (PAC-1) and its cellular co-localization with caspase-3

Small-molecule activation of procaspase-3 to caspase-3 as a personalized anticancer strategy

Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma.

Regulation of caspase activation and apoptosis by cellular zinc fluxes and zinc deprivation: A review.

Preparation of the caspase-3/7 substrate Ac-DEVD-pNA by solution-phase peptide synthesis

An uncleavable procaspase-3 mutant has a lower catalytic efficiency but an active site similar to that of mature caspase-3.

In silico prediction of blood-brain barrier permeation.

P304

7232-7241

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4410044

http://www.w3.org/2001/XMLSchema#string

P356

10.1158/0008-5472.CAN-10-0766

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

70

http://www.w3.org/2001/XMLSchema#string

P50

Quinn P Peterson

P577

2010-09-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

46169896

http://www.w3.org/2001/XMLSchema#string

P698

20823163

http://www.w3.org/2001/XMLSchema#string

P932

3113694

http://www.w3.org/2001/XMLSchema#string